Cardiovascular diseases are the world's leading cause of death, and high blood pressure, or hypertension, affects more than 1 ...

Renin converts angiotensinogen into angiotensin I, which ACE then converts into angiotensin II, a vasoconstrictor. ACE inhibitors and ARBs lower blood pressure by acting on different steps of this ...

The validity as well as the usefulness of measuring components of the renin-angiotensin-aldosterone system in the diagnosis and treatment of patients with elevated blood pressure (BP) has been ...

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...

High blood pressure, or hypertension, affects more than 1 billion people globally. Many of them are prescribed angiotensin-converting enzyme inhibitors—better known as ACE-1 inhibitors (ACEIs)—and/or ...

China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension: Shanghai, China Tuesday, April 22, 2025, 18:00 Hrs [IST] Ro ...

RN1871 is designed to silence AGT mRNA expression in the liver, precisely inhibiting the production of the key precursor protein in the Renin-Angiotensin ... rn1871-a-novel-angiotensinogen-agt ...